Iovance Biotherapeutics Inc [IOVA] stock is trading at $8.73, up 3.44%. An important factor to consider is whether the stock is rising or falling in short-term value. The IOVA shares have gain 19.92% over the last week, with a monthly amount glided 1.28%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on November 20, 2023, when Goldman initiated its Buy rating and assigned the stock a price target of $12. Previously, Barclays reaffirmed its Overweight rating on September 18, 2023, and dropped its price target to $18. On May 30, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $17 on the stock. Piper Sandler upgraded its rating to a Overweight and raised its price target to $14 on January 27, 2023. Goldman downgraded its rating to Neutral for this stock on December 09, 2022, and downed its price target to $6. In a note dated October 31, 2022, Guggenheim initiated an Neutral rating.
Iovance Biotherapeutics Inc [IOVA] stock has fluctuated between $3.21 and $18.33 over the past year. Currently, Wall Street analysts expect the stock to reach $23.71 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $8.73 at the most recent close of the market. An investor can expect a potential return of 171.59% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
Gross Profit Margin for this corporation currently stands at -16.33% with Operating Profit Margin at -245.5%, Pretax Profit Margin comes in at -238.72%, and Net Profit Margin reading is -236.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -0.71 and Total Capital is -0.59. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.39 points at the first support level, and at 8.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.09, and for the 2nd resistance point, it is at 9.44.
Ratios To Look Out For
For context, Iovance Biotherapeutics Inc’s Current Ratio is 4.63. On the other hand, the Quick Ratio is 4.42, and the Cash Ratio is 1.61. Considering the valuation of this stock, the price to sales ratio is 1285.75, the price to book ratio is 3.59.
Transactions by insiders
Recent insider trading involved Rothbaum Wayne P., Director, that happened on Feb 20 ’24 when 5.0 million shares were purchased. Director, MCPEAK MERRILL A completed a deal on Feb 20 ’24 to buy 0.25 million shares. Meanwhile, Director Dukes Iain D. bought 32000.0 shares on Feb 20 ’24.
